Clinical Research Directory
Browse clinical research sites, groups, and studies.
Comparison of Elagolix and OCPs in Reducing Endometriosis Associated Pelvic Pain
Sponsor: Pak Emirates Military Hospital
Summary
This study is designed to provide direct evidence on the relative effectiveness and safety of Elagolix versus OCPs, helping physicians make more tailored treatment decisions.
Official title: Comparison of Efficacy and Safety of Elagolix and OCPs in Reducing Endometriosis Associated Pelvic Pain
Key Details
Gender
FEMALE
Age Range
18 Years - 45 Years
Study Type
INTERVENTIONAL
Enrollment
90
Start Date
2026-05-01
Completion Date
2026-11-01
Last Updated
2026-04-16
Healthy Volunteers
No
Conditions
Interventions
Elagolix
Elagolix will be administered at 150 mg once daily in this study.
Oral Contraceptive (OC)
In this study, administered once daily in a continuous 28-day cycles for 3 months
Locations (1)
Pak Emirates Military Hospital
Rawalpindi, Punjab Province, Pakistan